274. Osteogenesis Imperfecta Clinical trials / Disease details

Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-003228-22-NL (EUCTR)	13/01/2021	27/11/2020	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;Netherlands;United Kingdom
2	EUCTR2016-003228-22-IE (EUCTR)	22/06/2017	03/11/2016	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Clasteon Product Name: Clasteon Trade Name: Calcichew D3 Product Name: Calcichew D3 Trade Name: Fultium-D3 800IU capsules Product Name: Fultium-D3 800IU capsules Trade Name: Prolia Product Name: Prolia	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;Netherlands;United Kingdom
3	EUCTR2016-003228-22-GB (EUCTR)	14/12/2016	19/10/2016	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]	Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos	University of Edinburgh	NHS Lothian	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 4	Ireland;United Kingdom
4	JPRN-UMIN000010615	2013/04/30	30/04/2013	Clinical study on efficacy of alendronate infusion for pediatric osteogenesis imperfecta (including severe form)	Clinical study on efficacy of alendronate infusion for pediatric osteogenesis imperfecta (including severe form) - Alendronate infusion for osteogenesis imperfecta	osteogenesis imperfecta	Eighteen micrograms (2 ml)/kg of alendronate will be infused in 1 hour every 4 weeks. The study duration is 6 months. When the patient's BMD reaches to the normal range for age, treatment with alendronate will be finished. When the patient's BMD does not reach to the normal range for age, alendronate will be continued for another 6 months.	Tohoku University School of Medicine, Department of Pediatrics	NULL	Complete: follow-up continuing	Not applicable	15years-old	Male and Female	10	Not applicable	Japan
5	NCT02303873 (ClinicalTrials.gov)	March 2007	19/11/2014	Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta	Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study	Osteogenesis Imperfecta	Drug: Alendronate	Peking Union Medical College Hospital	National Natural Science Foundation of China	Completed	N/A	18 Years	Both	99	Phase 4	NULL
6	NCT00159419 (ClinicalTrials.gov)	August 1999	7/9/2005	Bisphosphonate Therapy for Osteogenesis Imperfecta	Bisphosphonate Therapy for Osteogenesis Imperfecta	Osteogenesis Imperfecta;Osteoporosis;Paget Disease of Bone	Drug: Alendronate;Drug: Pamidronate	Indiana University School of Medicine	NULL	Completed	3 Years	21 Years	All	18	Phase 4	United States